Patents by Inventor Martin Pulé

Martin Pulé has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND REAGENTS FOR ANALYSING NUCLEIC ACIDS FROM SINGLE CELLS
    Publication number: 20210348213
    Abstract: The present invention relates to a partition library which comprises a plurality of partitions which are useful for the analysis of the transcriptional response of a CAR to a target antigen. Further, the present invention relates to assays for the analysis of the transcriptional response of a CAR to a target antigen. The present invention also relates to kits comprising the plurality of partitions.
    Type: Application
    Filed: October 10, 2019
    Publication date: November 11, 2021
    Inventors: Biao Ma, Preeta Datta, Yuchen Bai, Shimobi Onuoha, Martin Pulé
  • METHODS AND REAGENT FOR ANALYSING NUCLEIC ACIDS FROM INDIVIDUAL CELLS
    Publication number: 20210332411
    Abstract: The present disclosure relates to a bispecific reagent and a detection agent which are useful for the identification of an antibody-producing cell which produces an antibody that binds specifically to a target antigen. Further, the present disclosure relates to an assay for the identification of an antibody-producing cell which produces an antibody that binds specifically to a target antigen. The present disclosure also relates to kits comprising the bispecific reagent and the detection agent.
    Type: Application
    Filed: October 10, 2019
    Publication date: October 28, 2021
    Inventors: Biao Ma, Leo Kassimatis, Rosalind Gealy, Yuchen Bai, Shimobi Onuoha, Martin Pulé
  • POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY
    Publication number: 20210308240
    Abstract: The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd10-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd10-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer.
    Type: Application
    Filed: January 12, 2021
    Publication date: October 7, 2021
    Inventors: Martin Pulé, Brian Philip
  • CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210309716
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising a CD21? binding domain, a transmembrane domain and an intracellular domain.
    Type: Application
    Filed: May 15, 2019
    Publication date: October 7, 2021
    Inventor: Martin PULÉ
  • Chimeric protein
    Patent number: 11103532
    Abstract: The present invention provides a chimeric protein having the formula: Casp-Ht1-Ht2 wherein Casp is a caspase domain; Ht1 is a first heterodimerization domain; and Ht2 is a second heterodimerization domain and wherein, in the presence of a chemical inducer of dimcrization (CID), an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains. The invention also provides a cell comprising such a protein and its use in adoptive cell therapy.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: August 31, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Ryan Trowbridge, Edward Hodgkin
  • T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptor
    Patent number: 11091532
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 17, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
  • CAR-T CELLS EXPRESSING AN INHIBITORY ANTI-TGF-BETA-RECEPTOR II SINGLE DOMAIN ANTIBODY
    Publication number: 20210244762
    Abstract: The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) or transgenic T cell receptor (TCR) and secretes an antibody which binds a transforming growth factor beta receptor (T?R).
    Type: Application
    Filed: May 10, 2019
    Publication date: August 12, 2021
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Alex Kinna, Simon Thomas, Mathieu Ferrari, Marco Della Peruta, Phillip Wu
  • Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain
    Patent number: 11058722
    Abstract: The present invention provides a chimeric antigen-receptor (CAR)-forming polypeptide comprising: (i) an antigen-binding domain; (ii) a coiled-coil spacer domain; (iii) a transmembrane domain; and (iv) an endodomain. The invention also provides a multimeric CAR formed by association of a plurality of CAR-forming polypeptides by virtue of association of their coiled-coil spacer domains.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: July 13, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba
  • CELL
    Publication number: 20210187026
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, and wherein each of the first and second CARs is an activating CAR comprising an activating endodomain.
    Type: Application
    Filed: October 29, 2020
    Publication date: June 24, 2021
    Inventors: Martin Pulé, Khai Kong, Shaun Cordoba
  • Chimeric antigen receptor (CAR) comprising a CD19-binding domain
    Patent number: 11034750
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: June 15, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
  • CELL
    Publication number: 20210154229
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, wherein the spacer of the first CAR is different to the spacer of the second CAR and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.
    Type: Application
    Filed: September 4, 2020
    Publication date: May 27, 2021
    Inventors: Martin Pulé, Khai Kong, Shaun Cordoba
  • CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR OR ENGINEERED TCR AND COMPRISING A NUCLEOTIDE SEQUENCE WHICH IS SELECTIVELY EXPRESSED
    Publication number: 20210130775
    Abstract: The present invention provides a cell which expresses a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), the cell comprising a nucleotide sequence of interest (NOI) which is selectively expressed by the cell depending on: i) the differentiation/exhaustion state of the cell; or ii) the presence of an environmental metabolite in the microenvironment of the cell.
    Type: Application
    Filed: August 1, 2018
    Publication date: May 6, 2021
    Inventors: Martin Pulé, Shaun Cordoba, Maria Stavrou, Vijay Peddareddigari, Paul Smith
  • CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210113618
    Abstract: The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.
    Type: Application
    Filed: May 15, 2019
    Publication date: April 22, 2021
    Inventors: Martin Pulé, Evangelia Kokalaki, Shaun Cordoba, Shimobi Onuoha, Simon Thomas, Biao Ma, Mathieu Ferrari
  • Chimeric antigen receptor (CAR) comprising a CD22-binding domain
    Patent number: 10981970
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: April 20, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
  • Chimeric antigen receptor
    Patent number: 10975162
    Abstract: The present invention relates to chimeric antigen receptor (CAR) which binds the cancer antigen disialoganglioside (GD2). T cells expressing such a CAR are useful in the treatment of cancerous diseases such as neuroblastoma.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: April 13, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, John Anderson, Simon Thomas
  • CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210101959
    Abstract: The present invention provides a chimeric antigen recept- or (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 8, 2021
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Ben Draper
  • CELL
    Publication number: 20210095003
    Abstract: The present invention relates to a cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) a chimeric TNF receptor (TNFR) which comprises (a) a binding domain which is capable of binding a TNFR ligand; and (b) a TNFR signalling domain.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 1, 2021
    Inventors: Martin Pulé, Marco Della Peruta
  • Retroviral and lentiviral vectors
    Patent number: 10954530
    Abstract: The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and/or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and/or the cytokine-based T-cell activating transmembrane protein.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: March 23, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Leila Mekkaoui
  • Marker-suicide gene useful in adoptive cell therapy
    Patent number: 10925943
    Abstract: The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd1O-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd1O-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: February 23, 2021
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Brian Philip
  • Chimeric antigen receptor
    Patent number: 10919951
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising; (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: February 16, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Ben Draper